SCHEMBL1171665

SCHEMBL1171665

NC1=NC(N)(c2ccc(OCCN3CCOCC3)cc2)NC=C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
HPGD P15428 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
LTA4H P09960 2/20 0.46
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALDH1A1 P00352 2/20 0.44
BCHE P06276 1/20 0.44
MAOA P21397 1/20 0.44
ACHE P22303 1/20 0.44
MAOB P27338 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4468291 0.94 HRH3 (0.52) CYP1A2ALDH1A1TSHRMAPK1CHRM2
SCHEMBL1171785 0.88 LTA4H (0.45) HPGDNPC1RAB9ALTA4HALDH1A1
SCHEMBL1172660 0.77 MAPT (0.41) HPGDNPC1RAB9ACYP1A2ALDH1A1
SCHEMBL1172171 0.77 LTA4H (0.47) LTA4HALDH1A1TSHRKDM4EMAPK1
SCHEMBL1171872 0.74 NCF1 (0.41) ALDH1A1TSHRKDM4EMAPK1GAA
SCHEMBL4462873 0.74 KEAP1 (0.44) LTA4HCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL374497 0.73 LTA4H (0.67) CA12CA1CA2CA7CA9
Hydrochloric Acid SCHEMBL14742325 0.72 NPC1 (0.68) CA12CA1CA2CA7CA9
SCHEMBL14204158 0.72 CA12 (0.65) CA12CA1CA2CA7CA9
Hydrochloric Acid SCHEMBL2385707 0.72 NPC1 (0.68) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046108-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2011-02-24 US disclosed
EP-1981856-A2 PYRIMIDINE DERIVATIVES AstraZeneca AB (SE) 2008-10-22 EP disclosed
WO-2007085833-A2 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046108-A1 PYRIMIDINE DERIVATIVES EPHB4, EPHB1, EPHB3 CA12 4489/4885CA1 4634/4885CA2 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.